Low C6orf141 Expression is Significantly Associated with a Poor Prognosis in Patients with Oral Cancer

Abstract

C6orf141 (Chromosome 6 open reading frame 141) is a novel gene, and its role in oral cancer progression remains unclear. C6orf141 expression in oral squamous cell carcinoma (OSCC) and adjacent normal tissues from 428 patients was examined through immunohistochemistry (IHC). Our results revealed that C6orf141 expression was significantly reduced in OSCC compared with adjacent normal tissues. Low C6orf141 expression was significantly associated with a poor American Joint Committee on Cancer pathological stage (P < 0.001), T classification (P = 0.002), and pN stage (P = 0.032). Kaplan–Meier curves revealed that low C6orf141 expression was significantly associated with shorter disease-specific survival (DSS) in patients with OSCC (log-rank P = 0.007). Multivariate analysis indicated that low C6orf141 expression was an independent prognostic biomarker for DSS (adjusted hazard ratio = 1.34; 95% confidence interval = 1.10–1.81; P = 0.05). Additionally, ectopic C6orf141 expression could significantly suppress oral cancer cell proliferation, colony formation, and migratory and invasive abilities. Xenograft tumor growth assay revealed that C6orf141 could significantly suppress oral tumor growth in vivo. Our results suggest that C6orf141 plays a novel tumor-suppressive role in oral cancer cell growth and motility. Furthermore, C6orf141 dysfunction could be a potential prognostic biomarker for OSCC and provide new therapeutic strategies in the future.

Evaluation of synuclein-γ levels by novel monoclonal antibody in saliva and cancer tissues from oral squamous cell carcinoma patients

“…All tissues, as well as salivary samples, were from our hospital and the First Affiliated Hospital of Xinjiang Medical University. 94 surgically resected specimens including 30 cases of matched adjacent normal tissues were taken from OSCC patients who underwent surgery between 2010 and 2018 [12]. The diagnosis of OSCC was confirmed by histopathology and staging according to the UICC TNM classification and comprised 74 Stage I/II tumors and 20 Stage III/IV tumors.…”

Transcriptome-wide analysis and modelling of prognostic alternative splicing signatures in invasive breast cancer: a prospective clinical study

“…Low C6orf141 expression was associated with poor prognosis in other cancers 51 . The exon-specific qRT-PCR is applied to detect AS events and has been proved necessary in evaluating gene expression at single exon level for transcriptional biomarker research, especially in detecting AS events, in which it performed equally well or even better compared to ordinary gene qRT-PCR 52 . We found that expression of HERC4(exon 23) and EPHX2(exon 7) was higher in SD group, this confirmed our results of bioinformatic analysis that exon skip of HERC4 and EPHX2 is are protective factors.…”

“…DDX39B, an RNA helicase, is involved in various cellular processes. Its overexpression promotes the global translation and cell proliferation by upregulating pre-ribosomal RNA, which leads to oncogenesis 52 . DDX39B also regulates several AS events that are associated with the pathway of sphingolipid metabolism and poor prognosis of kidney renal clear cell carcinoma 26 .…”

Phytochemically Derived Zingerone Nanoparticles Inhibit Cell Proliferation, Invasion and Metastasis in Human Oral Squamous Cell Carcinoma

“…Three human oral squamous cell carcinoma (OSCC) cell lines, including Ca9-22 (the gingival SCC cells), Cal-27, and SAS (the tongue SCC cells), were cultured in DMEM supplemented with 10% fetal bovine serum (Gibco, HyClone, GE Healthcare Life Science, Logan, UT, USA) and 1% penicillin/streptomycin (Primocin, Invivogen, San Diego, CA, USA) [30]. These cell lines were incubated under humidified conditions in 95% air and 5% CO 2 at 37 • C. Zingerone was purchased from Sigma-Aldrich (Rehovot, Israel) and was used without any purification.…”